A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00001992
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie rgp120/HIV-1IIIB vaccine immunogenicity in HIV-1 seropositive adults?
How does rgp120/HIV-1IIIB vaccine compare to standard-of-care antiretroviral therapies in HIV-1 patients?
Which biomarkers correlate with immune response to rgp120/HIV-1IIIB vaccine in HIV-1 seropositive volunteers?
What adverse events were observed in Genentech's Phase I HIV-1IIIB vaccine trial and how were they managed?
Are there combination approaches involving rgp120 vaccine and other HIV-1 therapeutics showing improved outcomes?
Trial Locations
- Locations (1)
Walter Reed Army Institute of Research
🇺🇸Rockville, Maryland, United States
Walter Reed Army Institute of Research🇺🇸Rockville, Maryland, United States